MedDay Announces Full Enrollment for MD1003 Phase III

Biotin is an emerging therapy for the treatment of secondary progressive MS.

MedDay Announces Full Enrollment for MD1003 Phase III

Postby ton » Fri Nov 09, 2018 11:14 am

User avatar
ton
Family Member
 
Posts: 74
Joined: Thu May 27, 2010 2:00 pm

Advertisement

Return to Biotin (Qizenday, Cerenday, MD1003)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service